2025-02-08 - Analysis Report
## Merck & Co Inc (MRK) Stock Report

**0) Executive Summary:**

Merck & Co Inc (MRK) is a leading global healthcare company.  This report analyzes MRK's recent performance against the S&P 500 (VOO), considering price movements, financial statements, and key indicators like RSI and PPO.  Significant underperformance relative to the S&P 500 is observed.

**1) Performance Comparison with S&P 500:**

Merck & Co Inc is a global pharmaceutical company.

* **MRK Cumulative Return:** 44.89%
* **VOO (S&P 500) Cumulative Return:** 120.63%
* **Return Difference:** -75.7%  MRK significantly underperformed the S&P 500.  The relative underperformance, considering historical volatility, is at the lowest percentile (0.0).


**Alpha and Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | -2.0% | 11.8% | -0.30 | 1.10 | 110.0 |
| 2016-2018  | 46.0% | 11.8% | 0.28 | 1.54 | 154.0 |
| 2017-2019  | 44.0% | 11.8% | 0.14 | 1.88 | 188.2 |
| 2018-2020  | 32.0% | 9.4% | 0.05 | 1.75 | 174.7 |
| 2019-2021  | 3.0% | 14.3% | -0.68 | 1.78 | 177.8 |
| 2020-2022  | 47.0% | 14.3% | 0.38 | 2.66 | 265.6 |
| 2021-2023  | 55.0% | 14.3% | 0.32 | 2.68 | 268.3 |
| 2022-2024  | 21.0% | 9.5% | -0.12 | 2.52 | 251.5 |
| 2023-2025  | -41.0% | 10.5% | -1.03 | 2.23 | 222.6 |

The analysis shows fluctuating alpha and high beta (above 1), indicating significant market sensitivity and inconsistent outperformance relative to the benchmark.  Note that the provided MDD (Maximum Drawdown) values seem inconsistent with the CAGR (Compound Annual Growth Rate) values in some years, requiring further investigation.

**2) Recent Price Movement:**

* **Closing Price:** $88.05
* **Last Market Price:** $87.97
* **5-Day Moving Average:** $93.41
* **20-Day Moving Average:** $97.11
* **60-Day Moving Average:** $98.74

The stock price is currently below all three moving averages, suggesting a downtrend.  The recent slight price decrease (-$0.08) is not significant enough to indicate a major event.

**3) Technical Indicators:**

* **RSI:** 23.94 (Significantly below 30, indicating oversold conditions)
* **PPO:** -0.99 (Negative, suggesting bearish momentum)
* **20-Day Relative Divergence Change:** -5.9% (Short-term bearish trend)
* **Expected Return (vs. S&P 500):** 727.5% (This extremely high number requires further justification and context.  It's unrealistic to expect such a high return.)

The technical indicators point to a bearish outlook.  However, the extremely high expected return needs clarification, as it is unlikely.

**4) Recent Earnings Analysis:**

| Date       | EPS  | Revenue       |
|------------|------|---------------|
| 2024-11-06 | $1.25 | $16.66 B      |
| 2024-08-05 | $2.15 | $16.11 B      |
| 2024-05-03 | $1.88 | $15.78 B      |
| 2023-11-03 | $1.87 | $15.96 B      |
| 2024-11-06 | $1.87 | $15.96 B      | *(Duplicate entry, likely an error)*


There's a duplicate entry for 2024-11-06.  Earnings are somewhat volatile, with a noticeable decrease in EPS in the most recent quarter. Further analysis is needed to interpret the trend properly.  Revenue appears relatively stable.

**5) Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue    | Profit Margin |
|---------|------------|---------------|
| 2024-09-30 | $16.66B   | 75.51%        |
| 2024-06-30 | $16.11B   | 76.76%        |
| 2024-03-31 | $15.78B   | 77.56%        |
| 2023-12-31 | $14.63B   | 73.26%        |
| 2023-09-30 | $15.96B   | 73.29%        |

**Capital and Profitability:**

| Quarter | Equity    | ROE     |
|---------|------------|---------|
| 2024-09-30 | $44.50B   | 7.09%   |
| 2024-06-30 | $43.58B   | 12.52%  |
| 2024-03-31 | $40.36B   | 11.80%  |
| 2023-12-31 | $37.58B   | -3.26%  |
| 2023-09-30 | $41.25B   | 11.50%  |

Revenue shows relatively stable growth. Profit margins are high but have fluctuated.  ROE has been volatile, showing a significant negative value in Q4 2023.

**6) Overall Analysis:**

MRK has significantly underperformed the S&P 500 over the analyzed period. While the company shows high profit margins and relatively stable revenue,  recent earnings show volatility and the negative ROE in Q4 2023 is concerning. Technical indicators suggest an oversold condition, but the significant underperformance relative to the market is a major concern. The extraordinarily high projected long-term return needs substantiation. A deeper dive into the reasons for underperformance (e.g., specific drug performance, market competition, etc.) is required before drawing definitive conclusions about the future outlook. The data inconsistencies (e.g., duplicate entries in earnings, inconsistencies between CAGR and MDD) need resolution.
